KZIA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kazia Therapeutics Ltd (KZIA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has a positive analyst rating with an increased price target, encouraging clinical trial results, and no significant negative catalysts. While there are no strong trading signals today, the technical indicators and options data suggest a stable entry point.
The MACD histogram is positive at 0.372, indicating bullish momentum, though it is contracting. RSI is neutral at 57.755, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its pivot level of 8.027, with resistance at 9.883 and support at 6.17.
H.C. Wainwright raised the price target to $18 from $13 and maintained a Buy rating, citing encouraging Phase 1 study results for paxalisib in treating triple-negative breast cancer.
No significant hedge fund or insider trading trends. No recent news or congress trading data available.
No financial data available for analysis.
H.C. Wainwright increased the price target from $13 to $18 and maintained a Buy rating, citing positive clinical trial results.
